Mineralys Therapeutics, Inc. Cash Flow Statement
MLYS / Health Care|3 years of annual SEC 10-K data (FY2022-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
Mineralys Therapeutics, Inc. used $166M in operating cash flow and negative free cash flow of $166M in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Net Income | -$177.8M | -$71.9M | -$29.8M |
| Depreciation & Amortization | $43.0K | $0 | - |
| Operating Cash Flow | -$166.3M | -$81.2M | -$29.2M |
| Capital Expenditures | $96.0K | $0 | - |
| Free Cash Flow | -$166.4M | -$81.2M | - |